Smokeless tobacco - An overview

Beitrage zur Tabakforschung International/ Contributions to Tobacco Research

Volumn 23, Issue 5, 2009, Pages 248-276

  Klus, Hubert ^a   Kunze, Michael ^b   König, Steffen ^c   Pöschl, Ernst ^c  

^a Universität Wien ^*  (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c Pöschl Tabak GmbH and Co KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTIANA TABACUM;

EID: 70449629383     PISSN: 0173783X     EISSN: 16129237     Source Type: Journal    
DOI: 10.2478/cttr-2013-0865     Document Type: Article

References (215)

1. U. S. Department of Health and Human Services: Smoking and Health. A National Status Report. 2nd Edition; Washington DC: DHHS Publication Nr. (CDC) 87-8396 (Revised 02/90), Rockville, Maryland, 1986
2. Thielen, A., H. Klus, and L. Müller: Tobacco smoke: unraveling a controversial subject; Exp. Toxicol. Pathol. 60 (2008) 141-156.
3. Gupta, P. C., P. R. Murti, and R. B. Bhonsle: Epidemiology of cancer by tobacco products and the significance of TSNA; Crit. Rev. Toxicol. 26 (1996) 183-198.
4. Hoffmann, D. and M. V. Djordjevic: Chemical composition and carcinogenicity of smokeless tobacco; Adv. Dent. Res. 11 (1997) 322-329.
5. Poschl, E.: Schnupftabak Lexikon; Pöschl Tabak, Landshut, Germany, 2004, pp. 15-26.
6. Kozlowski, S.: Snuff in former Poland [Der Schnupftabak im früheren Polen]; Fachl. Mitt. österr. Tabakregie II/1 (1902) 20-24.
7. Rodu, B. and C. Jansson: Smokeless tobacco and oral cancer: a review of the risks and determinants; Crit. Rev. Oral Biol. Med. 15 (2004) 252-263
8. Stepanov, I., J. Jensen, D., Hatsukami, and S. S. Hecht: New and traditional smokeless tobacco: Comparison of toxicant and carcinogen levels; Nicotine Tob. Res. 10 (2008) 1773-1782
9. Rogozinski, J.: Smokeless tobacco in the Western World 1550-1950; Praeger Publishers, New York, 1990, pp. 42-44.
10. McGuirt, W. F. and A. Wray: Oral carcinoma and smokeless tobacco use: a clinical profile. In: Smokeless tobacco or health. An international perspective; US Department of Health and Human Services, Smoking and tobacco control monographs, Vol. 2; NCI Publication No. 93-3461, 1993, pp. 91-95..
11. Federal Trade Commission: Smokelss Tobacco Report for the years 2002 to 2005.; 2007, (accessed September 2009) http://www2.ftc.gov/reports/tobacco/02-05 smokeless0623105.pdf
12. Swedish Match: The Gothiatek Standard (accessed September 2009) ; www. Swedishmatch.com/en/snusand-health/our-quality-standard-GothiaTek/ GothiaTekstandards.
13. Ramström, L.: Snuff: an alternative nicotine delivery system; in: Nicotine and public health, edited by R. Ferrence, J. Slade, R. Room and M. Pope, American Public Health Association, Washington, D. C., pp. 159-178.
14. Statistics Sweden, Unit of Social Wellfare: Alkohol - och tobaksbruk [Use of alcohol and tobacco]. Levnadsförhallanden Report 114, 2007
15. Deutsches Krebsforschungszentrum (Hrsg.) : Rauchlose Tabakprodukte: Jede Form von Tabak ist gesundheitschädlich [Smokeless tobacco products: Tobacco in any form is harmful]; Heidelberg, 2006, pp. 25-27.
16. rd International Conference on Smokeless Tobacco, Stockholm, Sweden, Sept. 22-25, 2002
17. Tricker, A. R. and R. Preussmann: The occurrence of N-nitroso compounds in zarda tobacco; Cancer Lett 42 (1988) 113-118
18. McNeill, A., R. Bedi, S. Islam, M. N. Alkhatib, and R. West: Levels of toxins in oral tobacco products in the UK; Tob. Control 15 (2006) 64-67.
19. Ratsch, C: Schamanenpflanze Tabak, Band 2, Das Rauchkraut erobert die alte Welt; Nachtschatten-Verlag A. G., 2003, pp 403.
20. Harrison, D. F. N.: Snuff-Its use and abuse. Brit. Med. 12 (1964) 1649-1651.
21. Centre de Cooperation pour les Recherches Scientific relatives au Tabac (CORESTA) : Coresta catalogue des Nicotiana; Paris, 1984.
22. Preißecker, K.: Das Kapitel "Kau-und Schnupftabak" im Codex Alimentarius Austriaca [The chapter "Chewing tobacco and Snuff' of the Codex Alimentarius Austriaca]; Fachl. Mitt. österr. Tabakregie 17/1-3 (1917) 1-16.
23. Bundesrepublik österreich: Bundesgesetz über das Herstellen und das In-Verkehrbringen von Tabakerzeugnissen sowie die Werbung für Tabakerzeugnisse und den Nichtraucherschutz (Tabakgesetz), BGBl. Nr. 431/1995, zuletzt geändert durch das Bundesgesetz BGB1.1 Nr. 120/2008.
24. European Commission: Directive 2001/37/EC of the European Parliament and of the Council of 5 June 2004 on the approximation of the laws, regulations and administrative provisions of the Member States concerning the manufacture, presentation and sale of tobacco products. Off. J. Eur. Commun. LI94 (2001) 26-34.
25. Bundesrepublik Deutschland: "Vorlaufiges Tabakgesetz" [Preliminary Tobacco Law] Tabakverordnung vom 9. September 1997 (BGBL. I S. 2296), zuletzt geändert durch Artikel 1 der Verordnung vom 21. Dezember 2006 (BGBl. I S. 3365).
26. Bundesrepublik Deutschland: Aromenverordnung vom 22. Dezember 1981, Artikel 22 der Verordnung zur Neuordnung lebensmittelrechtlicher Kennzeichnungsvorschriften in der Fassung vom 2. Mai 2006 (BGBl. I. 1127), zuletzt geändert durch Art. 1 der Verordnung vom 30. September 2008 (BGBl 11911).
27. Bundesrepublik Deutschland: Verordnung über die Zulassung von Zusatzstoffen zu Lebensmitteln zu technologischen Zwecken, Zusatzstoff- Zulassungsverordnung vom 29. Januar 1998 (BGBl I 230, 231), zuletzt geändert durch Art. 3 der Verordnung vom 30. September 2008.
28. Bundesrepublik Deutschland: Verordnung über Höchstmengen an Rückständen von Pflanzenschutz-und Schädlingsbekä mpfungsmitteln, Düngemittel und sonstigen Mitteln in und auf Lebensmitteln und Tabakerzeugnissen, Rückstands-Höchstmengenverordnung - RHmV vom 21. Oktober 1999 (BGBl I S. 2082, ber. 2002 S. 1004), zuletzt geandert durch Art. 3 des Gesetzes vom 29. Juni 2009 9 (BGBl. I S. 1659).
29. Pershagen, G.: Smokeless tobacco; Brit. Med. Bull. 52 (1996) 50-57.
30. Berka, F.: The essential oils used in tobacco manufacture [Die bei der Tabakfabrikation in Verwendung stehenden ätherischen öle] Fachl. Mitt. österr. Tabakregie, 111/3 (1903) 6-14.
31. Berka, F.: A contribution to the knowledge of the aromatic ingredients used by the k.k. Tobacco Monopoly [Ein Beitrag zur Kenntnis der bei der Tabakregie in Verwendung stehenden aromatischen Ingredienzien] Fachl. Mitt. österr. Tabakregie, 4/2 (1904) 41-50.
32. Department of Health: Permitted additives to tobacco products in the United Kingdom; London, October 2003. http://www.advisorybodies.doh.gov. uk/scoth/technicaladvisorygroup/additiveslist.pdf
33. st, 1995.
34. Swedish Food Regulations. Food Act of 2006, SFS 2006: 804.
35. Rodgman, A. and T. A. Perfetti: The chemical components of tobacco and tobacco smoke; CRC Press, Boca Raton, Fl, 2009.
36. de Wit, H. and J. Zacny : Abuse potentials of nicotine replacement therapies; CNS Drugs 4 (1995) 456-468.
37. Benowitz, N. L.: Clinical pharmacology of transdermal nicotine; Eur. J. Pharm. Biopharm. 41 (1995) 168-174.
38. Benowitz, N. L., H. Porchet, L. Sheiner, and P. Jacob III: Nicotine absorption and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum; Clin. Pharmacol. Ther. 44 (1988) 23-28.
39. Russel, M. A. H., M. J. Jarvis, G. Devitt, and C. Feyerabend: Nicotine intake by snuff users; Brit. Med. J. 283 (1981) 814-817.
40. Guthrie, S. K., J. K. Zubieta, L. Ohl, L. Ni, R. A. Koeppe, S. Minoshima, E. F. Domino: Arterial/venous plasma nicotine concentrations following nicotine nasal spray; Eur. J. Clin. Pharmacol. 55 (1999) 639-643.
41. Fant, R. V., L. L. Owen, and J. E. Henningfield: Nicotine replacement therapy; Prim. Care 26 (1999) 633-652.
42. Fagerstrom, K.: Nicotine-replacement therapies; In: Nicotine and Public Health edited by R. Ferrence, J. Slade, R. Room and M. Pope; American Public Health Association, Washington, D. C. 2000.
43. Holm, H., M. J. Jarvis, M. A. Russell, and C. Feyerabend: Nicotine intake and dependence in Swedish snuff takers; Psychopharmacology 108 (1992) 507-511.
44. Bhide, S. V., J. Nair, G. B. Maru, U. J. Nair, B. V. Kameshwar Rao, M. K. Chakraborty, and K. D. Brunnemann: Tobacco-specific N-nitrosamines [TSNA] in green mature and processed tobacco leaves from India; Beitr. Tabakforsch. Int. 14 (1987) 29-32.
45. th TCRC, Winston-Salem, NC., October 3-5, 1973.
46. Klus, H. and H. Kuhn: Untersuchungen über die nichtflüchtigen N-Nitrosamine der Tabakalkaloide [Investigations concerning the non-volatile N-nitrosamines of the tobacco alkaloids]; Fachl. Mitt. Austria Tabakwerke A. G., 16 (1975) 307-317.
47. Bush, L. P., M. Cui, H. Shi, H. R. Burton, F. F. Fannin, L. Lei, and N. Due: Formation of tobacco-specific nitrosamines in air cured tobacco; Rec. Adv. Tob. Sci. 27 (2001) 23-46.
48. DeRoton, C., A. Wiernik, I Wahlberg, and B. Vidal: Factors influencing the formation of tobacco-specific nitrosamines in French air-cured tobaccos in trials and at the farm level; Beitr. Tabakforsch. Int. 21 (2005) 305-320.
49. Staaf, M., S. Back, A. Wiernik, I. Wahlberg, R. C. Long, and J. H. Young: Formation of tobacco-specific nitrosamines (TSNA) during air-curing: Conditions and control; Beitr. Tabakforsch. Int. 21 (2005) 321-330.
50. Peele, D. M., M. G. Riddick, M. E. Edwards, J. S. Gentry, and T. B. Nestor: Formation of tobacco-specific nitrosamines in flue-cured tobacco; Rec. Adv. Tob. Sci. 27 (2001) 3-12.
51. International Agency on Research on Cancer, Lyon, France: IARC monographs on the evaluation of carcinogenic risk to humans Vol. 37: Tobacco habits other than smoking; Betel-quid and areca-nut chewing and some related nitrosamines. Lyon, 1985
52. International Agency on Research on Cancer, Lyon, France: IARC monographs on the evaluation of carcinogenic risk to humans Suppl. 7: Overall evaluations of Carcinogenicity: an updating of IARC monographs 1 to 42. Lyon, 1987
53. International Agency on Research on Cancer, Lyon, France: IARC monographs on the evaluation of carcinogenic risk to humans. Vol 89: Smokeless tobacco and some tobacco-specific N-nitrosamines. IARC, Lyon, France, 2007.
54. Hoffmann D., J. D. Adams, K. D. Brunnemann, and S. S. Hecht: Assessment of tobacco specific N-nitrosamines in tobacco products; Cancer Res. 39 (1979) 2505-2509.
55. Hoffmann, D. and J. D. Adams: Carcinogenic tobaccospecific N-nitrosamines in snuff and in the saliva of snuff dippers; Cancer Res. 41 (1981) 4305-4308.
56. Hoffmann D., N. H. Harley, I. Fisenne, J. D. Adams, and K. D. Brunnemann: Carcinogenic agents in snuff; J. Natl. Cancer Inst. 76 (1986) 435-437.
57. Hoffmann D., J. D. Adams, D. Lisk, I. Fisenne, and K. D. Brunnemann: Toxic and carcinogenic agents in dry and moist snuff; J. Natl. Cancer Inst. 79 (1987) 1281-1286.
58. Hoffmann D., K. D. Brunnemann, and S. Venitt: Carcinogenic nitrosamines in oral snuff - Letter to the editor; Lancet 1 (1988) 1232
59. Brunnemann, K. D., L. Genoble, and D. Hoffmann: N-nitrosamines in chewing tobacco: an international comparison; J. Agric. Food Chem. 33 (1985) 1178-1181.
60. Brunnemann, K. D., A. Rivenson, J. D. Adams, S. S. Hecht, and D. Hoffmann: A study of snuff carcinogenesis; in: Bartsch, H., i. K. O'Neill and R. Schulte-Hermann: Relevance of N-nitroso compounds to human Cancer, IARC Scientific publications, Lyon, France, 84 (1987) 456-459.
61. Djordjevic, M. V., K. D. Brunnemann, and D. Hoffmann: Identification and analysis of a nicotine-derived N-nitrosamino acid and other nitrosamino acids in tobacco; Carcinogenesis 10 (1989) 1725-1731.
62. Chamberlain, W. J., W. S. Schlotzhauer, and O. T. Chortyk: Chemical composition of nonsmoking tobacco products; J. Agric. Food Chem. 36 (1988) 48-50.
63. Djordjevic, M. V., K. D. Brunnemann, and D. Hoffmann: The need for regulation of carcinogenic N-nitrosamines in oral snuff; Food Chem. Toxicol. 31 (1993) 497-501.
64. Brunnemann, K. D., J. Qi, and D. Hoffmann: Chemical profile of two types of oral snuff tobacco; Food Chem. Toxicol. 40 (2002) 1699-1703.
65. Hoffmann, D., M. V. Djordjevic, J. Fan, E. Zang, T. Glynn, and G. N. Connolly: Five leading U. S. commercial brands of moist snuff in 1994: assessment of carcinogenic N-nitrosamines; J. Natl. Cancer Inst. 87 (1995) 1862-1869.
66. Jansson, C., A. Paccou, and B.-G. Österdahl: Analysis of tobacco specific N-nitrosamines in snuff by ethyl acetate extraction and liquid chromatography-tandem mass spectrometry; J. Chromat. A 1008 (2003) 135-143.
67. Stepanov, I., J. Jensen, D. Hatsukami, and S. S. Hecht: Tobacco-specific nitrosamines in new tobacco products; Nicotine Tob. Res. 8 (2006) 309-313.
68. Osterdahl, B.-G., C. Jansson, and A. Paccou: Decreased levels of tobacco specific N-nitrosamines in moist snuff on the Swedish market; J Agric. Food Chem. 52 (2004) 5085-5088.
69. Rickert, W. S., P. J. Joza, A. H. Trivedi, R. A. Momin, W. G. Wagstaff, and J. H. Lauterbach: Chemical and toxicological characterization of commercial smokeless tobacco products available on the Canadian market; Regul. Toxicol. Pharmacol. 53 (2009) 121-133.
70. Poschl, E.: 2004, unpublished results.
71. Brunnemann, K. D. and D. Hoffmann: Chemical composition of smokeless tobacco products; in: Smokeless tobacco or health. An international perspective (Smoking and Tobacco Control Monograph No. 2; NIH Publ. No. 93-34-61), Bethesda, MD, National Cancer Institute, 1992. Pp. 96-108.
72. Poschl E.: 2008, unpublished results.
73. Curvall, M., L. Romert, E. Norlén, and C. R. Enzell: Mutagen levels in urine from snuff users, cigarette smokers and non tobacco users-A comparison; Mut. Res. 188 (1987) 105-110.
74. Jansson, T., L. Romert, J. Magnussonm, and D. Jenssen: Genotoxicity testing of extracts of a Swedish moist oral snuff; Mut. Res. 261 (1991) 101-115.
75. Health Canada: Bacterial reverse mutation assay for mainstream tobacco smoke; Official Method T-501, second Ed., 2004.
76. Health Canada: Neutral red uptake assay for mainstream tobacco smoke; Official Method T-502, second Ed., 2004.
77. Health Canada: In vitro micronucleus assay for mainstream tobacco smoke; Official Method T-503, second Ed., 2004.
78. Rickert, W. S., W. G. Wright, A. H. Trivedi, R. A. Momin, and J. H. Lauterbach: A comparative study of the mutagenicity of various types of tobacco products; Regul. Toxicol. Pharmacol. 48 (2007) 320-330.
79. Critchley, J. A. and B. Unal: Health effects associated with smokeless tobacco: a systematic review; Thorax 58 (2003) 435-433.
80. Roth, H. D., A. B. Roth, and X. Lui: Health risks of smoking compared to Swedish snus; Inhal. Toxicol. 17 (2005) 741-748.
81. Broadstock, M.: Sytematic review of the health effects of modified smokeless tobacco products; NZHTA Report Vol. 10, 2007.
82. Nitzkin, J. L. and B. Rodu: AAPHP Resolution and White Paper: The case for harm reduction for control of tobacco-related illness and death; American Association of Public Health Physicians. October 26, 2008.
83. Boffetta, P., S. S. Hecht, N. Gray, P. Gupta, and K. Straif: Smokeless tobacco and cancer; Lancet Oncol. 9 (2008) 667-675.
84. Lee, P. N. and J. Hamling: The relation between smokeless tobacco and cancer in Northern Europe and North America. A commentary on differences between the conclusions reached by two recent reviews; BMC Cancer 9 (2009) 256.
85. Lee, P. N. and J. S. Hamling: Systematic review of the relation between smokeless tobacco and cancer in Europe and North America; BMC Medicine 7 (2009) 36.
86. Luo, J., W. Ye, K. Zendehdel, J. Adami, H.-O. Adami, P. Boffetta, and O. Nyrén: Oral use of Swedish moist snuff (snus) and risk for cancer of the mouth, lung, and pancreas in male construction workers: a retrospective cohort study; Lancet 369 (2007) 2015-2020.
87. Boffetta, P., B. Aagnes, E. Weiderpass, and A. Andersen: Smokeless tobacco use and the risk of cancer of the pancreas and other organs; Int. J. Cancer 114 (2005) 992-995.
88. Zendehdel, K., O. Nyren, J. Luo, P. W. Dickman, P. Boffetta, A. Englund, and W. Ye: Risk of gastroesophageal cancer among smokers and users of Scandinavian moist snuff; Int. J. Cancer 122 (2008) 1095-1099.
89. Wynder, E. L., I. J. Brass, and R. M. Feldman: A study of the etiologic factors in cancer of the mouth; Cancer 10 (1957) 1300-1323.
90. Winn D. M., W J. Blot, C. M. Shy, L. W. Pickle, A. Toledo, and J. F. Fraumeni Jr: Snuff dipping and oral cancer among women in the southern United States; New Engl. J. Med. 304 (1981) 745-749.
91. Mashberg A., P. Boffetta, R. Winkelman, and L. Garfinkel: Tobacco smoking, alcohol drinking and cancer of the oral cavity and oropharynx among U. S. veterans; Cancer 72 (1993) 1369-1375.
92. Bouquot, J. E. and R. L. Meckstroth: Oral cancer in a tobacco-chewing US population - no apparent increased incidence or mortality; Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 86 (1998) 697-706.
93. Schildt, E. B., M. Eriksson, L. Hardell, and A. Magnuson: Oral snuff, smoking habits and alcohol consumption in relation to oral cancer in a Swedish casecontrol study; Int. J. Cancer 77 (1998) 341-346.
94. Lewin, F., S. E. Norell, H. Johansson, P. Gustavsson, J. Wennerberg, A. Biorklund, and L. E. Rutqvist: Smoking tobacco, oral snuff, and alcohol in the etiology of squamous cell carcinoma of the head and neck. A population-based case-referent study in Sweden; Cancer 82 (1998) 1367-1375.
95. Rosenquist, K., J. Wennerberg, E.-B. Schildt, A. Bladström, B. G. Hansson, and G. Andersson: Use of Swedish moist snuff, smoking and alkohol consumption in the aetiology of oral and oropharyngeal squamous cell carcinoma. A population-based case-control study in southern Sweden; Acta Oto-Laryngol. 125 (2005) 991-998. (Pubitemid 41306312)
96. Accortt, N. A., J. W. Waterbor, C. Beall, and G. Howard: Chronic disease mortality in a cohort of smokeless tobacco users; Am. J. Epidemiol. 156 (2002) 730-737.
97. Rodu, B. and P. Cole: Smokeless tobacco use and cancer of the upper respiratory tract; Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 93 (2002) 511-515.
98. Weitkunat, R., E. Sander, and P. N. Lee: Meta-analysis of the relation between European and American smokeless tobacco and oral cancer; BMC Public Health 7 (2007) 334.
99. Conway, D.: Oral cancer risk and smokeless tobacco products - clouded by smoke? Evid. Based Dent. 9 (2008) 114-115
100. Roosaar, A., A. L. V. Johansson, G. Sandborgh-Englund, T. Axéll, and O. Nyrén: Cancer and mortality among users and nonusers of snus; Int. J. Cancer 123 (2008) 168-173.
101. Pichler, K: Typische Pigmentierung der Wangenschleimhaut bei Tabak-Kauern [Typical pigmentation oft he cheek mucosa of tobacco chewers]; Wiener Med. Wchnschr. 6 (1916).
102. Bouquot, J. E. and R. J. Gorlin: Leukoplakia, lichen planus, and other oral keratoses in 23, 616 white Americans over the age of 35 years; Oral Surg. Oral Med. Oral Pathol. 61 (1986) 373-381.
103. Grady, D., J. Greene, T. E. Daniels, V. L. Ernster, P. B. Robertson, W. Hauck, D. Greenspan, J. Greenspan, and S. Silverman Jr: Oral mucosal lesions found in smokeless tobacco users; J. Am. Dent. Assoc. 121 (1990) 117-123.
104. Sinusas, K., J. G. Coroso, M. D. Sopher, and B. F. Carbtree: Smokeless tobacco use and oral pathology in a professional baseball organization; J. Fam. Pract. 34 (1992) 713-718.
105. Greer Jr, R. O. and T. C. Poulson: Oral tissue alterations associated with the use of smokeless tobaccos by teenagers - Part 1. Clinical findings; Oral Surg. Oral Med. Ora Pathol. 56 (1983) 275-284.
106. Greer, R. O., T. C. Poulson, M. E. Boone, J. E. Lindenmuth, and L. Crosby: Smokeless tobacco-associated oral changes in juvenile, adult and geriatric patients: clinical and histomorphologic features; Gerodontics 2 (1986) 87-98.
107. Greene, J. C., V. L. Ernster, D. G. Grady, P. B. Robertson, M. M. Walsh, and L. A. Stillmann: Oral mucosal lesions: clinical findings in relation to smokeless tobacco use among US baseball players; Monograph. 2. Smokeless tobacco or health, an international perspective; NIH publication No. 93-4361 (1993) 41-50.
108. Andersson, G. and T. Axéll: Clinical appearance of lesions associated with the use of loose and portion-bag packed Swedish moist snuff: a comparative study; J. Oral Pathol. Med. 18 (1989) 2-7. (Pubitemid 19178080)
109. Roosaar, A., A. L. V. Johansson, G. Sandborg-Englund, O. Nyrén, and T. Axell: A long term follow-up study on the natural course of snus-induced lesions among Swedish snus users; Int. J. Cancer 119 (2006) 392-397.
110. Kallischnigg, G., R. Weitkunat, and P. N. Lee: Systematic review of the relation between smokeless tobacco and non-neoplastic oral diseases in Europe and the United States; BMC Oral Health 8 (2008) 13.
111. l. Brinton L. A., W. J. Blot, J. A. Becker, D. M. Winn, J. P. Browder, J. C. Farmer Jr, and J. F. Fraumeni Jr: A casecontrol study of cancers of the nasal cavity and paranasal sinuses; Am. J. Epidemiol. 119 (1984) 896-906.
112. Sapundzhiev, N. and J. A. Werner: Nasal snuff: historical review and health related aspects; J. Laryngol. Otol. 117 (2003) 686-691.
113. Pfaue D., M. Tisch, and H. Maier: Krebs durch Schnupftabak? [Cancer by the use of nasal snuff?]; HNO 51 (2003) 193-196.
114. Lagergren, J., R. Bergström, A. Lindgren, and O. Nyrén: The role of tobacco, snuff and alcohol use in the aetiology of cancer oft the oesophagus and gastric cardia; Int. J. Cancer 85 (2000) 340-346.
115. Ye, W., A. M. Ekström, L.-E. Hansson, R. Bergström, and O. Nyrén: Tobacco, alcohol and the risk of gastric cancer by sub-site and histologic type; Int. J. Cancer 83 (1999) 223-229.
116. Alguacil J. and D. T. Silverman: Smokeless and other non-cigarette tobacco use and pancreatic cancer: A casecontrol study based on direct interviews; Cancer Epidemiol. Biomarkers Prev. 13 (2004) 55-58.
117. NiIsson, R.: Possible carcinogenicity of smokeless tobacco-Letter to the Editor; Int. J. Cancer 118 (2006) 1582-1583.
118. Rutqvist, L. E. and F. Lewin: Flawed methods-Letter to the Editor; Int. J. Cancer 118 (2006) 1581.
119. Ramstrom, L.: Re: "Smokeless tobacco use and risk of cancer of the pancreas and other organs" by Boffetta et al. - Letter to the Editor; Int. J. Cancer 118 (2006) 1584.
120. Rodu, B. and P. Cole: A deficient study of smokeless tobacco use and cancer - Letter to the Editor; Int. J. Cancer 118 (2006) 1585.
121. Hassan, M. M., J. L. Abbruzzese, M. L. Bondy, R. A. Wolff, J..-N. Vauthey, P. W. Pisters, D. B. Evans, R. Kahn, R. Lenzi, L. Jiao, and D. Li: Passive smoking and the use of noncigarette tobacco products in association with risk for pancreatic cancer: A case-control study; Cancer 109 (2007) 2547-2556.
122. Sponsiello-Wang, Z., R. Weitkunat, and P. N. Lee: Systematic review of the relation between smokeless tobacco and cancer of the pancreas in Europe and North America; BMC Cancer 8 (2008) 356.
123. Accortt, N. A., J. W. Waterbor, C. Beall, and G. Howard: Cancer incidence among a cohort of smokeless tobacco users (United States) ; Cancer Causes Control 16 (2005) 1107-1115.
124. Henley, S. J., M. J. Thun, C. Connell, and E. E. Calle: Two large prospective studies of mortality among men who used snuff or chewing tobacco (United States) ; Cancer Causes Control 16 (2005) 347-358.
125. Foulds, J. and L. Ramstrom: Causal effects of smokeless tobacco on mortality in CPS-I and CPS-II?-Letter to the Editor; Cancer Causes Control 17 (2006) 227-228.
126. Hecht, S. S.: Letter to the editor, response to J. Foulds and L. Ramström; Cancer Causes and Control 17 (2006) 227-228 and to
127. S. J. Henley, M. J. Thun, C. Connell, and E. E. Calle; Cancer Causes and Control 16 (2005) 347-358 (2005).
128. How smokeless tobacco can cause lung cancer; Cancer Causes Control 17 (2006) 859-860.
129. Henley, S. J. and M. J. Thun: Letter to the editor, response to J. Foulds and L. Ramström: Causal effects of smokeless tobacco on mortality in CPS-I and CPS-II; Cancer Causes Control 17 (2006) 857-858.
130. Lee, P. N.: Circulatory disease and smokeless tobacco in Western populations: a review of the evidence; Int. J. Epidemiol. 36 (2007) 789-804.
131. Hergens, M. P., M. Lambe, G. Pershagen, and W. Ye: Risk of hypertension amongst Swedish male snuff users: a prospective study; J. Intern. Med. 264 (2008) 187-194.
132. Gupta, R., H. Gurm, and J. R. Bartholomew: Smokeless tobacco and cardiovascular risk; Arch. Intern. Med. 164 (2004) 1845-1849.
133. Arabi, Z.: Metabolic and cardiovascular effects of smokeless tobacco: J. Cardiometab. Syndr. (JCMS) 1 (2006) 345-350.
134. Bolinder, G., L. Alfredsson, A. Englund, and U. de Faire: Smokeless tobacco use and increased cardiovascular mortality among Swedish construction workers; Am. J. Public Health 84 (1994) 399-404.
135. Rodu, B. and P. Cole: Excess mortality in smokeless tobacco users not meaningful. Am. J. Public Health 85 (1995) 118-119.
136. Hergens, M. P., A. Ahlbom, T. Andersson, and G. Pershagen: Swedish moist snuff and myocardial infarction among men; Epidemiology 16 (2005) 12-16.
137. Ahlbom, A., U. A. Olsson, and G. Pershagen: Hälsorisker med Snus [Health Risks by Snuff] Position paper; Stockholm: Swedish National Board of Health and Wellfare; 1997.
138. Hergens, M. P., L. Alfredsson, G. Bolinder, M. Lambe, G. Pershagen, and W. Ye: Long-term use of Swedish moist snuff and the risk of myocardial infarction amongst men; J. Intern. Med. 262 (2007) 351-359,
139. Erratum: ibid. p. 590
140. Huhtasaari, F., K. Asplund, V. Lundberg, B. Stegmayr, and P. O. Wester: Tobacco and myocardial infarction: is snuff less dangerous than cigarettes? Brit. Med. J. 305 (1992) 1252-1256.
141. Huhtasaari, F., V. Lundberg, M. Eliasson, U. Janlert, and K. Asplund: Smokeless tobacco as a possible risk factor for myocardial infarction: a population-based study in middle-aged men; J. Am. Coll. Cardiol. 34 (1999) 1784-1790.
142. Asplund, K., S. Nasic, U. Janlert, and B. Stegmayr: Smokeless tobacco as a possible risk factor for stroke in men: a nested case-control study; Stroke 34 (2003) 1754-1759.
143. Johansson, S. E., K. Sundquist, J. Qvist, and J. Sundquist: Smokeless tobacco and coronary heart disease: a 12-year follow-up study; Eur. J. Cardiovasc. Prev. Rehabil. 12 (2005) 387-392.
144. Haglund, B., M. Eliasson, M. Stenbeck, and M. Rosén: Is moist snuff associated with excess risk of IHD or stroke? A longitudinal follow-up of snuff users in Sweden; Scand. J. Public Health 35 (2007) 618-622.
145. Wennberg, P., M. Eliasson, G. Hallmans, L. Johansson, K. Boman, and J.-H. Jansson: The risk of myocardial infarction and sudden cardic death amongst snuff users with or without a previous history of smoking; J. Intern. Med. 262 (2007) 360-367.
146. Hergens, M. P., M. Lambe, G. Pershagen, A. Terent, and W. Ye: Smokeless tobacco and the risk of stroke; Epidemiology 19 (2008) 794-799.
147. Mushtaq, N., D. M. Thompson, J. Morris, W. L. Owen, and V. J. Skaggs: Smokeless tobacco and risk of cardiovascular disease; APHA Scientific Session, Boston MA, November 4-8, 2006.
148. Asplund, K: Smokeless tobacco and cardiovascular disease; Progr. Cardiovasc. Dis. 45 (2003) 383-394.
149. Critchley, J. A. and B. Unal: Is smokeless tobacco a risk factor for coronary heart diseases? A systematic review of epidemiological studies; Europ. J. Cardiovas, Prev. Rehab. 11 (2004) 101-112.
150. Hirsch, J.-M., J. Hedner, L. Wernstedt, J. Lundberg, and T. Hedner: Hemodynamic effects of the use of snuff; Clin. Pharmacol. Ther. 52 (1992) 394-401.
151. Bolinder, G. M., B. O. Ahlborg, and J. H. Lindell: Use of smokeless tobacco: blood pressure elevation and other health hazards found in a large-scale population survey; J. Intern. Med. 232 (1992) 327-334.
152. Ekenvall, L. and L. E. Lindblad: Vibrationsutlösta Raynaudfenomen och nicotinkonsumation-en preliminär rapport [Vibration induced white fingers and nicotine-a preliminary report]; Opusc. Med. 30 (1985) 28-31.
153. Boffetta, P. and K. Straif: Use of smokeless tobacco and risk of myocardial infarction and stroke: systematic review with meta-analysis; Brit. Med. J. 339 (2009) b3060, doi: 10.1136/bmj.b3060 (published 18 August 2009)
154. Koskinen, L.-O. D. and P. C. Blomstedt: Smoking and non-smoking tobacco as risk factors in subarachnoid haemorrhage; Acta Neurol. Scand. 114 (2006) 33-37.
155. Persson, P.-G., G. Hellers, and A. Ahlbom: Use of oral moist snuff and inflammatory bowel disease; Int. J. Epidemiol. 22 (1993) 1101-1103.
156. Elliasson, M., K. Asplund, S. Nasic, and B. Rodu: Influence of smoking and snus on the prevalence and incidence of type 2 diabetes amongst men: the northern Sweden MONICA study; J. Intern. Med. 256 (2004) 101-110.
157. Fernberg, P., A. Odenbro, R. Bellocco, P. Boffetta, Y. Pawitan, and J. Adami: Tobacco use, body mass index and the risk of malignant lymphomas-a nationwide cohort study in Sweden; Int. J. Cancer 118 (2006) 2298-2302.
158. Norberg, M., H. Stenlund, B. Lindahl, K. Boman, and L. Weinehall: Contribution of Swedish moist snuff to the metabolic syndrome: A wolf in sheep's clothing? Scand. J. Public Health 34 (2006) 576-583.
159. Wandell, P. E., G. Bolinder, U. de Faire, and M.-L. Hellénius: Association between metabolic effects and tobacco use in 60-year-old Swedish men; Eur. J. Epidemiology 23 (2008) 431-434.
160. Fang, R., R. Bellocco, M. A. Hernán, and W. Ye: Smoking, snuff dipping and the risk of amyotrophic lateral sclerosis-a prospective cohort study; Neuroepidemiology 27 (2006) 217-221.
161. England, L. J., R. J. Levine, J. L. Mills, M. A. Klebanoff, K. F. Yu, and S. Cnattingius: Adverse pregnancy outcomes in snuff users; Am. J. Obstet. Gynecol. 189 (2003) 939-943.
162. Nilsson R.: A qualitative and quantitative risk assessment of snuff dipping; Regul. Toxicol. Pharmacol. 28 (1998) 1-16.
163. Hecht S. S., A. Rivenson, J. Braley, J. DiBello, J. D. Adams, and D. Hoffmann: Induction of oral cavity tumors in F344 rats by tobacco-specific nitrosamines and snuff; Cancer Res. 46 (1986) 4162-4166.
164. Rivenson, A., D. Hoffmann, B. Prokopczyk, S. Amin, and S. S. Hecht: Induction of lung and exocrine pancreas tumors in F344 rats by tobacco-specific and Areca-derived N-nitrosamines; Cancer Res. 48 (1988) 6912-6917.
165. Hecht, S. S., S. G. Carmella, I. Stepanov, J. Jensen, A. Anderson, and D. K. Hatsukami: Metabolism of the tobacco-specific carcinogen 4-(methylnitrosamino) -1 - (3-pyridyl) -1-butanone to its biomarker total NNAL in smokeless tobacco users; Cancer Epidemiol. Biomarkers Prev. 17 (2008) 732-735.
166. Kresty, L. A., S. G. Carmella, A. Borukhova, S. A. Akerkar, R. Gopalakrishnan, R. E. Harris, G. D. Stoner, and S. S. Hecht: Metabolites of a tobacco specific nitrosamine, 4-(methylnitrosamino) -1-(3-pyridyl) -1 - butanone (NNK), in the urine of smokeless tobacco users: relationship between urinary biomarkers and oral leukoplakia; Cancer Epidemiol. Biomarkers Prev. 5 (1996) 521-525.
167. Hecht, S. S., S. G. Carmella, S. E. Murphy, W. T. Riley, C. Le, X. Luo, M. Moony, and D. K. Hatsukami: Similar exposure to a tobacco-specific carcinogen in smokeless tobacco users and cigarette smokers; Cancer Epidemiol. Biomarkers Prev. 16 (2007) 1567-1572.
168. Hatsukami, D. K., C. Lemmonds, Y Zhang, S. E. Murphy, C. Le, S. G. Carmella, and S. S. Hecht: Evaluation of carcinogen exposure in people who used "reduced exposure" tobacco products; J. Natl. Cancer Inst. 96 (2004) 844-852.
169. British Thoracic Society: Smoking withdrawal in hospital patients: Factors associated with outcome; Thorax 39 (1984) 651-656.
170. British Thoracic Society, Research Commettee: Smoking cessation in patients: two further studies by the British Thoracic Society; Thorax 45 (1990) 835-840.
171. Cahill, K., L. Stead, and T. Lancaster: A preliminary benefit-risk assessment of varenicline in smoking cessation; Drug Saf. 32 (2009) 119-135.
172. Jansson T., L. Romert, J. Magnusson, and D. Jenssen: Genotoxicity testing of extracts of a Swedish moist oral snuff; Mutat. Res. 261 (1991) 101-115.
173. Brown B. G., A. J. Borschke, and D. J. Doolittle: An analysis of the role of tobacco-specific nitrosamines in the carcinogenicity of tobacco smoke; Nonlinearity Biol. Toxicol. Med. 1 (2003) 179-198.
174. Enzell, C. R.: Terpenoid components in leaf and their relationship to smoking quality and aroma; Rec. Adv. Tob. Sci. 2 (1976) 32-60.
175. Garewal, H.: Antioxidants in oral cancer prevention; Am. J. Clin. Nutr. 62 (1995) 1410S-1416S.
176. Garewal H. S., R. V. Katz, F. Meyskens, J. Pitcock, D. Morse, S. Friedman, Y. Peng, D. G. Pendrys, S. Mayne, D. Alberts, T. Kierschk, and E. Graver: β-carotene produces sustained remissions in patients with oral leukoplakia: results of a multicenter prospective trial; Arch. Otolaryngol. Head Neck Surg. 125 (1999) 1305-1310.
177. Wahlberg, I. and T. Ringberger: Smokeless tobacco; In: World Agriculture Series; edited by D. L. Davis and M. T. Nielsen, Tobacco Production, Chemistry and Technology. Blackwell Science, London, 1999, pp. 452-460.
178. Kallianos, A. G.: Phenolics and acids in leaf and their relationship to smoking quality and aroma; Rec. Adv. Tob. Sci. 2 (1976) 61-79.
179. Chung, F-L., M. A. Morse, K. I. Eklind, and Y. Xu: Inhibiton of the tobacco-specific nitrosamine-induced lung tumorigenesis by compounds derived from cruciferous vegetables and green tea; Ann. N. Y. Acad. Sci. 686 (1993) 186-201.
180. Yang, C. S., G. Y. Yang, J. M. Landau, S. Kim, and J. Liao: Tea and tea polyphenols inhibit cell hyperproliferation, lung tumorigenesis, and tumor progression; Exp. Lung Res. 24 (1998) 629-639.
181. Rodu B. and B. Ou: The antioxidant properties of tobacco; Tobacco Science 44 (2000) 71-73.
182. Prior, R. L. and G. Cao: Analysis of botanicals and dietary supplements for antioxidant capacity: a review; J. Assoc. Off. Anal. Chem. Int. 83 (2000) 950-956.
183. th Tobacco Chemists Research Conference, Raleigh, NC, 2003.
184. Ahlbom A., U. A. Olsson, and G. Pershagen: Health hazards of moist snuff; National Board on Health and Welfare. Stockholm, Sweden, 1997.
185. Savitz, D. A., R. E. Meyer, J. M. Tanzer, S. S. Mirvish, and F. Lewin: Public health implications of smokeless tobacco use as a harm reduction strategy; Am. J. Publ. Health 96 (2006) 1934-1939.
186. Tso, T. C., N. Harley, and L. Alexander: Source of lead-210 and polonium-210 in tobacco; Science 153 (1966) 880-882.
187. Lugon-Moulin, N., M. Zang, F. Gadani, L. Rossi, D. Koller, M. Krauss, and G. J. Wagner: Critical review of the science and options for reducing cadmium in tobacco (Nicotiana tabacum L.) and other plants; Adv. Agron. 83 (2004) 111-180. (Pubitemid 39753878)
188. Idris, A. M., S. O. Ibrahim, E. N. Vasstrand, A. C. Johannessen, J. R. Lillehaug, B. Magnusson, M. Wallström, J. M. Hirsch, and R. Nilsen: The Swedish snus and the Sudanese toombak: are they different? Oral Oncol. 34 (1998) 558-566.
189. Rodu, B., B. Stegmayr, S. Nasic, and K. Asplund: Impact of smokeless tobacco use on smoking in northern Sweden; J. Intern. Med. 252 (2002) 398-404.
190. Rodu, B., B. Stegmayr, S. Nasic, P. Cole, and K. Asplund: Evolving patterns of tobacco use in northern Sweden. J. Intern. Med. 253 (2003) 660-665.
191. Stegmayr, B., M. Eliasson, and B. Rodu: The decline of smoking in Northern Sweden. Scand. J. Public Health, 33 (2005) 321-324.
192. Gilljam H. and M. R. Galanti: Role of snus (oral moist snuff) in smoking cessation and smoking reduction in Sweden; Addiction 98 (2003) 1183-1189.
193. Ramström, L. M. and J. Foulds: Role of snus in initiation and cessation of tobacco smoking in Sweden; Tob. Control 15 (2006) 210-214.
194. Tomar, S. L.: Snuff use and smoking in U. S. men. Implications for harm reduction; Am. J. Prev. Med. 23 (2002) 143-149.
195. Lundqvist, G., H. Sandström, A. öhman, and L. Weinehall: Patterns of tobacco use: a 10-year follow-up study of smoking and snus habits in a middle-aged Swedish population; Scand. J. Public Health 37 (2009) 161-167.
196. Furberg, H., P. Lichtenstein, N. L. Pedersen, C. Bulik, and P. F. Sullivan: Cigarettes and oral snuff use in Sweden: prevalence and transitions; Addiction 101 (2006) 1509-1515.
197. Lindstrom M.: Nicotine replacement therapy, professional therapy, snuff use and tobacco smoking: a study of smoking cessation strategies in southern Sweden; Tob. Control: 16 (2007) 410-416.
198. Galanti, M. R., I. Rosendahl, and S. Wickholm: The development of tobacco use in adolescence among "snus starters" and "cigarette starters": An analysis of the Swedish "BROMS" cohort; Nicotine Tob. Res. 10 (2008) 315-323.
199. Lund, K. E., E. M. Tefre, A. Amundsen, and S. Nordlund: Røyking, bruk av snus og annen risikoatferd blant studenter [Cigarette smoking, use of snuff and other risk behavior among students]; Tidssrk. Nor. Legeforen 128 (2008) 1808-1811.
200. Zhu, S.-H., J. B. Wang, A. Hartman, Y. Zhuang, A. Gamst, J. T. Gibson, H. Gilljam, and M. R. Galanti: Quitting cigarettes completely or switching to smokeless tobacco: do US data replicate the Swedish results? Tob. Control 18 (2009) 82-87.
201. Cobb, CO., M. F. Weaver, and T. Eissenberg: Evaluating the acute effects of oral, non-combustible potential reduced exposure products marketed to smokers; Tob. Control, (2009), doi: 10.1136/tc2008.028993 (published 2 April 2009).
202. Stratton, K., P. Shetty, R. Wallace, and S. Bondurant: Clearing the smoke-Assessing the science base for tobacco harm reduction. National Academy of Science, Institute of Medicine; National Academy Press, Washington, D. C., 2001, pp. 27-28.
203. Bates, C., J. Britton, I. Campbell, T. Coleman, L. Cuthbertson, R. Edwards, C. Godfrey, K. Jamrozik, M. Jarvis, A. McNeill, D. Milner, and A. Woodcock: Protecting smokers, saving lives. Royal College of Physicians, London, 2002.
204. Bates, C., K. Fagerström, M. Jarvis, M. Kunze, A. McNeill, and L. Ramström: European Union policy on smokeless tobacco: A statement in favor of evidence based regulation for public health; Tob. Control 12 (2003) 360-367.
205. Levy, D. T., E. A. Mumford, K. M. Cummings, E. A. Gilpin, G. Giovino, A. Hyland, D. Sweanor, and K. E. Warner: The relative risk of a low-nitrosamine smokeless tobacco product compared with smoking cigarettes: estimates of a panel of experts; Cancer Epidemiol. Biomarkers Prevent. 13 (2004) 2035-2042.
206. Rodu, B. and P. Cole: T.: The burden of mortality from smoking: Comparing Sweden with other countries in the European Union; Eur. J. Epidemiol. 19 (2004) 129-131.
207. House Subcommittee on Commerce, Trade, and Consumer Protection, 3 June 2003; http//energy commerce.house.gov/reparchives/108/Hearings/06032 003hearing928/hearing.htm
208. Royal College of Physicians: Harm reduction in nicotine addiction. Helping people who can't quit. A report by the Tobacco Advisory Group of the Royal College of Physicians, RCP, London, 2007.
209. Rodu, B. and W. T. Godshall: Tobacco harm reduction: an alternative cessation strategy for inveterate smokers. Harm Reduction J. 3 (2006) 37.
210. Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) : Health effects of smokeless tobacco products, Preliminary Report; 2007.
211. Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) : Health effects of smokeless tobacco products; 2008.
212. Gartner, C. E., W. D. Hall, T. Vos, M. Y. Bertram, A. L. Wallace, and S. S. Lin: Assessment of Swedish snus for tobacco harm reduction: an epidemiological modelling study; Lancet 369 (2007) 2010-2014.
213. McKee, M., A. Gilmore and M. Lambe: Swedish snus for tobacco harm reduction - Letter to the editor; Lancet 370 (2007) 1206.
214. Gartner, C. E., W. D. Hall, T. Vos, M. Y. Bertram, and A. L. Wallace: Swedish snus for tobacco harm reduction -Authors' reply; Lancet 370 (2007) 1260-1261.
215. Britton, J. and R. Edwards: Tobacco smoking, harm reduction, and nicotine product regulation; Lancet 371 (2008) 441-445.